Next Article in Journal
Update on Renal Cell Carcinoma Diagnosis with Novel Imaging Approaches
Next Article in Special Issue
Prior Advanced Care Planning and Outcomes of Cardiopulmonary Resuscitation in the Emergency Department of a Comprehensive Cancer Center
Previous Article in Journal
Conventional versus Hepatic Arteriography and C-Arm CT-Guided Ablation of Liver Tumors (HepACAGA): A Comparative Analysis
Previous Article in Special Issue
End-of-Life Symptom Burden among Patients with Cancer Who Were Provided Medical Assistance in Dying (MAID): A Longitudinal Propensity-Score-Matched Cohort Study
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cancers
Volume 16
Issue 10
10.3390/cancers16101927
cancers-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Impact of Real-World Outpatient Cancer Rehabilitation Services on Health-Related Quality of Life of Cancer Survivors across 12 Diagnosis Types in the United States

by
Mackenzi Pergolotti
1,2,*,
Kelley C. Wood
1,
Tiffany D. Kendig
1 and
Stacye Mayo
1
1
ReVital Cancer Rehabilitation, Select Medical, Mechanicsburg, PA 17055, USA
2
Department of Occupational Therapy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
*
Author to whom correspondence should be addressed.
Cancers 2024, 16(10), 1927; https://doi.org/10.3390/cancers16101927
Submission received: 11 March 2024 / Revised: 6 May 2024 / Accepted: 11 May 2024 / Published: 18 May 2024
(This article belongs to the Special Issue Medical Complications and Supportive Care in Patients with Cancer)
Browse Figure
Review Reports Versions Notes

Abstract

:

Simple Summary

This is the first study to examine the impact of specialized community-based outpatient physical and occupational therapy on the health-related quality of life of cancer survivors with various cancers. Survivors who completed PT/OT reported significant improvements in physical and mental health, physical function, and social participation. Although more research is needed, these findings suggest cancer rehabilitation is an important strategy to meet HRQOL needs and lends support for inclusion as a standard of care.

Abstract

Compared to adults without cancer, cancer survivors report poorer health-related quality of life (HRQOL), which is associated with negative treatment outcomes and increased healthcare use. Cancer-specialized physical and occupational therapy (PT/OT) could optimize HRQOL; however, the impact among survivors with non-breast malignancies is unknown. This retrospective (2020–2022), observational, study of medical record data of 12 cancer types, examined pre/post-HRQOL among cancer survivors who completed PT/OT. PROMIS® HRQOL measures: Global Health (physical [GPH] and mental [GMH]), Physical Function (PF), and Ability to Participate in Social Roles and Activities (SRA) were evaluated using linear mixed effect models by cancer type, then compared to the minimal important change (MIC, 2 points). Survivors were 65.44 ± 12.84 years old (range: 19–91), male (54%), with a median of 12 visits. Improvements in GPH were significant (p < 0.05) for all cancer types and all achieved MIC. Improvements in GMH were significant for 11/12 cancer types and 8/12 achieved MIC. Improvements in PF were significant for all cancer types and all achieved the MIC. Improvements in SRA were significant for all cancer types and all groups achieved the MIC. We observed statistically and clinically significant improvements in HRQOL domains for each of the 12 cancer types evaluated.

1. Introduction

Compared to adults without cancer, adults living with or beyond cancer (cancer survivors) experience poorer health-related quality of life (HRQOL) [1,2]. Of the 18 million survivors living in the United States of America (USA), up to 75% report unmet needs in one or more domains of HRQOL, including physical or mental health, physical function, and social participation [3,4,5,6,7,8,9,10,11]. The risk for poorer cancer outcomes increases when domains of HRQOL are left unaddressed, including morbidity and mortality [12,13,14], poor treatment tolerance [15,16], increased caregiver burden [17,18], and increased use of long-term care and unplanned hospitalizations [19]. Declines in HRQOL are a population-based issue for cancer survivors and our healthcare system that will only grow with the significant increase in older adults with cancer [20], and meeting survivors’ HRQOL needs is critical to achieve better patient health and experience while optimizing costs. Although the cancer care team as a whole is accountable for addressing survivors’ HRQOL needs, the ability to identify these needs and provide targeted intervention is a long-standing challenge in oncology care [21,22].
Proposed solutions to this population-based issue include the integration of supportive services within the typical oncology workflow, such as outpatient cancer rehabilitation services (defined here as cancer-specialized physical and occupational therapy services (PT/OT)) [23]. PT/OT are skilled services covered by most insurances with the goal of reducing the negative impact of treatment-related side effects on daily life, improving functional independence, participation in life roles, and HRQOL [24]. Meta-analyses of controlled research studies demonstrate the efficacy of PT/OT interventions in alleviating treatment-related side effects (pain, lymphedema, fibrosis, atrophy, etc.) and optimizing functional independence (ability to complete self-care, daily or social activities, return to work, etc.) [25,26,27,28]. In addition, growing evidence shows participation in cancer rehabilitation interventions may result in cost savings to survivors and the healthcare system [29,30,31]. However, the limited generalizability of existing evidence is a barrier to understanding the population-level HRQOL benefits of community-based outpatient PT/OT services and may potentially limit access to care [23,32,33]. This is especially true for non-breast malignancies and medically complex populations, many of whom are excluded from medical clinical trials but experience high rates of functional and participation restrictions amenable to rehabilitation [1,23,26].
A systematic evaluation of practice-based evidence obtained from real-world, nationally representative outpatient PT/OT care is needed to understand the degree to which participation in these services may improve HRQOL for cancer survivors of multiple cancer types. To address this research–practice gap and public health needs, we performed a retrospective, pre/post, observational study of rehabilitation medical records, to better understand the impact of real-world PT/OT services on HRQOL outcomes for cases with non-breast malignancies (breast malignancies reported elsewhere) [34]. We hypothesized that we would observe significant improvement in HRQOL outcomes among individuals within each cancer type from initial evaluation to discharge.
Primary outcomes include global physical and mental health, and secondary outcomes include physical function and ability to participate in social roles and activities. All outcomes were collected during routine PT/OT services by licensed therapists with cancer-specific training, using Patient Reported Outcome Measurement Information System (PROMIS®) short forms.

2. Materials and Methods

This was a retrospective study of rehabilitation medical record data from patients who completed outpatient cancer PT/OT (N = 1415) over a two-year period (2020–2022) by a large rehabilitation network (ReVital Cancer Rehabilitation Program, Select Medical). The services were provided in 604 clinics across 21 states in the USA. Rehabilitation interventions were provided by cancer-specialized PT and/or OT and billed through insurance for skilled therapy as per typical practice. Rehabilitation interventions, visit frequency, and duration were determined by the evaluating therapist based on the clinical evaluation and the survivor’s individual needs and goals. We report the study methods following the Professional Society for Health Economics and Outcomes Research (ISPOR) checklist for retrospective studies [35].

2.1. Case Identification and Data Extraction

Rehabilitation cases that met the following criteria were included in the study: history of a non-breast malignancy (identified from ICD-10 codes), 18 years of age or older, discharged from PT/OT during the study period (January 2020 and September 2022), attended three or more PT/OT visits, and had the primary outcome measure available at initial evaluation (pre) and discharge (post). An honest broker used these criteria to identify eligible cases in the EMR (N = 1415) and create a de-identified dataset for analysis. Available case characteristics included age, sex, race, USA region, payer-type rehabilitation service type (PT/OT), ICD-10 codes, number of visits, and length of care (weeks). Cancer type was determined from ICD-10 codes.

2.2. PROMIS Measures and Scoring

Developed and validated by the National Institutes of Health (NIH), PROMIS measures are recommended to evaluate HRQOL in general and clinical populations due to high-precision and low-response burden [36,37,38,39,40]. Each PROMIS measure is scored using a T-score scale, where T-score of 50 represents the general population mean in the USA (standard deviation: 10) [37,38]. Higher T-scores indicate more of the domain being measured (i.e., global physical and mental health, physical function, ability to participate in social roles or activities) and have shown to be sensitive and specific to capture improvement or decline in HRQOL during or following cancer treatment [41]. The established minimal important change (MIC) is two to six points on the T-score scale [42]. We used 2 points as the threshold for clinically significant change in this study. Three PROMIS measures (with four domain scores) were recommended and routinely used by treating therapists of the national program due to high feasibility, sensitivity, and specificity for evaluating cancer survivors’ HRQOL [2,43,44,45,46,47]; these included the 10-item Global Health measure (scored with two domains, Global Physical Health [GPH] and Global Mental Health [GMH]) [48], the four-item Physical Function (PF) measure, and the four-item Ability to Participate in Social Roles and Activities (SRA) measure. We scored each measure into the appropriate T-score using established guidelines and categorized baseline T-scores using established cutoff points (e.g., GPH T-score below 42 categorized as fair-to-poor) [40].

2.3. Covariates

All covariates were extracted from the rehabilitation medical record and chosen based on availability and potential impact on the primary outcome. Covariates included in the model were as follows: age, sex, rehabilitation service type, visits, and length of care.

2.4. Statistical Analysis

We evaluated case characteristics descriptively using frequencies or measures of central tendency (mean ± SD or median, IQR), including the prevalence of impairment in each HRQOL domain at baseline as determined by the established PROMIS cut points (Figure 1) [40]. To identify cancer types with above-average levels of HRQOL impairment at baseline, we performed one-sample binomial testing (Figure 1). To examine change pre- to post-rehabilitation, in HRQOL measures among each cancer type, we used linear mixed effect models. Covariates included in each model are described in Table 1 and include age, sex, rehabilitation service type, number of visits, and length of care. From each model, we report the estimated marginal (EM) means and standard error (SE) at each timepoint (pre/post), EM mean change between timepoints, and the p-value for timepoint (main effect). Because a large portion of each group completed PT (93%) as compared to OT services, we adjusted all EM means to the rehabilitation service-type sample margins. Statistical analyses were completed using IBM SPSS Statistics (Version 28) or R (R version 4.0.1) [49]. Alpha was set to 0.05 for all hypothesis tests.

3. Results

On average, cases were 65.45 ± 12.84 years old, male (54%), and completed a median of 12 visits (IQR: 8.0 to 19.0) over 28 weeks (IQR: 9.1 to 80.0). Most completed PT (92.9%) versus OT (7.1%). Common cancer types included head and neck (n = 257, 18%), lung (n = 169, 12%), gynecologic (n = 158, 11%), and prostate (n = 146, 10%). All characteristics and the prevalence of each cancer type are reported in Table 1. Overall prevalence of HRQOL impairment at baseline was 54% in GPH, 20% in GMH, 78% in PF, and 60% in SRA (Figure 1). A significantly greater proportion of impairment was reported by cases with gastrointestinal (67.5%, p = 0.009), lung (66.3%, p < 0.001), and gynecologic (62.0%, p = 0.026) cancers for GPH; by cases with pancreatic (30%, p = 0.026) and multiple myeloma (27%, p = 0.042) for GMH; by cases with pancreatic (90.9%, p = 0.009), lung (90.8%, p < 0.001), brain/spinal cord/CNS (90.6%, p = 0.021), and gastrointestinal cancers (88.7%, p = 0.021) for PF; and by cases with pancreatic (80.3%, p < 0.001), gastrointestinal (72.9%, p = 0.019), lung (69.7%, p = 0.009), lymphoma (69.6%, p = 0.039), and leukemia (64.5%, p < 0.001) cancers for SRA. A significantly lower proportion of impairment was observed in head and neck for GPH (36.2%, p < 0.001), GMH (14.0%, p < 0.001), and PF (50.6%, p < 0.001).
Cancers 16 01927 g001
Figure 1. Percentage of cases reporting impairments in HRQOL domains at baseline, overall, and by cancer type. Abbreviations HRQOL, health-related quality of life. HRQOL impairment was determined using established cut points for each PROMIS® measure: (a) global physical health (T-score ≤ 41), (b) global mental health (T-score ≤ 39), (c) physical function (T-score ≤ 45), and (d) ability to participate in social roles and activities (T-score ≤ 45) [40]. * The within-group percentage of impairment was significantly different than the percentage of impairment observed overall, p < 0.05.
Figure 1. Percentage of cases reporting impairments in HRQOL domains at baseline, overall, and by cancer type. Abbreviations HRQOL, health-related quality of life. HRQOL impairment was determined using established cut points for each PROMIS® measure: (a) global physical health (T-score ≤ 41), (b) global mental health (T-score ≤ 39), (c) physical function (T-score ≤ 45), and (d) ability to participate in social roles and activities (T-score ≤ 45) [40]. * The within-group percentage of impairment was significantly different than the percentage of impairment observed overall, p < 0.05.
Cancers 16 01927 g001
From initial evaluation to discharge, HRQOL improved significantly overall and among each cancer type (all p < 0.05, Table 2, Table 3, Table 4 and Table 5). Improvements in GPH were significant (p < 0.05) for all cancer types (range: 2.93 [colorectal] to 5.15 [leukemia]), and all achieved MIC (Table 2). Improvements in GMH were significant for 11/12 cancer types (range: 1.83 [lung, prostate] to 3.24 [brain/CNS]), and 8/12 achieved MIC (Table 3). Of the cancer types that did not achieve the MIC for GMH, average improvements trended in that direction, ranging from 1.83 to 1.94. Improvements in PF were significant for all cancer types (range: 2.66 [head and neck] to 4.61 [leukemia]), and all achieved the MIC (Table 4). Improvements in SRA were significant for all cancer types (range: 2.16 [prostate] to 5.53 [leukemia]), and all groups achieved the MIC (Table 5).

4. Discussion

In this study of over 1400 adults, across 12 different cancer types, who completed outpatient cancer rehabilitation, we observed statistically and clinically significant improvements in each domain of HRQOL measured (physical and mental health, physical functioning, and social participation). This is the first study to evaluate the impact of cancer PT/OT on HRQOL in a large, nationally representative sample, participating in real-world outpatient community-based services. Furthermore, this is the first study to examine rehabilitation outcomes in 12 unique cancer types, many of which are understudied. In doing so, we provide a pragmatic and generalizable understanding of how patients within several different cancer populations may present on evaluation to rehabilitation and their potential for improvement. Coupled with existing research demonstrating the high prevalence of unmet HRQOL needs within the growing population of cancer survivors and the potential value of rehabilitation services in terms of patient outcomes [26], satisfaction [50], and cost-effectiveness [29,31], the findings of this study suggest that widespread participation in real-world cancer rehabilitation services could enhance HRQOL for cancer survivors at the population level and add value to oncology care.
In this study, we corroborate and build upon existing research and the findings of Feliciano and colleagues, who reported that compared to peers without cancer, those with cancer experience poorer HRQOL. In their recent prospective cohort study, the authors [1] reported women with breast, colorectal, endometrial, and lung cancer experienced a significant functional decline after diagnosis and, generally, did not recover to their prior level of functioning, nor to the level of women without cancer 10 years. In this study, we found similar findings at initial evaluation. Survivors reported at evaluation for outpatient PT/OT, their HRQOL scores were one to two standard deviations below the USA average (i.e., PROMIS T-score: 50). Using established PROMIS T-score cut-off values [40], we observed that 20–54% of survivors reported fair-to-poor global mental or physical health, and 60–78% reported mild-to-severe physical functioning and social participation needs. Recognizing that specific HRQOL needs and trajectory differ by cancer type [1,2], we also found clinically meaningful differences across cancer types on evaluation for rehabilitation. For example, survivors with pancreatic cancer had the lowest average scores for GPH, GMH, and SRA, while patients with lung and brain/spinal cord/nervous system cancers reported the lowest PF scores.
Although at baseline, average group scores were below USA norms for all HRQOL domains, average scores among several cancer types met or exceeded USA norms when discharged from cancer PT/OT. GMH scores for 4/13 types (head and neck, genitourinary, leukemia, prostate) and SRA scores for 2/13 cancer types (head and neck, leukemia) met or exceeded USA norms. The magnitude of improvement in HRQOL outcomes observed in this study was similar to or greater than the findings of previous meta-analyses and our previous evaluations of practice-based evidence [26,51,52,53]. We also observed differences in the magnitude of change across domains (see Table 2, Table 3, Table 4 and Table 5). For example, the leukemia (GPH and SRA), lung (PF), and genitourinary (GMH) groups experienced the greatest magnitude of improvement across the HRQOL domains. These diagnosis-specific differences are important for recognition and screening, triggering a referral, and during rehabilitation evaluation and intervention. Taken together, these results demonstrate that participation in rehabilitation elicits important improvements in some domains of HRQOL. Notably, improvements associated with cancer PT/OT allowed survivors to achieve HRQOL that was, at best, similar to individuals without cancer or, at least, greater than that observed for individuals in other studies who may not have had access to this supportive care service [54,55]. Because poor PROMIS HRQOL outcome scores have been closely associated with morbidity and mortality after cancer diagnosis [56,57], these results suggest that rehabilitation may also have a positive effect on these outcomes; however, more research is needed.
Patient-reported improvements in mental health (GMH) in this study were especially noteworthy. Mental health support is critical considering that up to 65% of individuals with cancer report high levels of distress and depressive or anxious symptoms [17,58,59,60]. In some cases, high levels of distress are related to unplanned healthcare use [61] and decreased adherence to cancer treatments [62]. However, statistically significant (12/13 groups) and clinically significant improvement in GMH was observed across all the 12 cancer-type groups. It is plausible that this may be due to the levels of distress and decreased mental health influenced by a change in one’s physical ability or level of independence [17,60,63]. Potentially, cancer PT/OT combined with other supportive services such as social work, rehabilitation psychology, and psycho-oncology could have an even greater impact on survivors’ mental health specifically and should be investigated.
The results of this study add to the literature in three ways: First, analysis of data from a large, nationally representative sample of cancer rehabilitation participants lends to the generalizability of findings to outpatient PT/OT interventions that survivors are likely to encounter in the United States. Cases were treated in 21 U.S. states, and the community-based nature of the PT/OT services provided is representative of where cancer care is increasingly provided in the United States. Therefore, the results may serve as an appropriate viewpoint allowing survivors or providers alike to anticipate the potential benefits of rehabilitation as well as provide a benchmark for comparison for rehabilitation providers regarding the quality of outcomes achieved. Second, this study evaluated the impact of PT/OT across 12 non-breast malignancies, where evidence of interventions for these populations is severely limited, yet higher rates of functional and participation restrictions remain. Third, the use of PROMIS outcomes in this study has two key benefits: (1) ability to easily compare the HRQOL of our sample to the USA general population, and (2) ability to demonstrate the use of cancer PT/OT as a means to health by demonstrating a ‘dotted line’ to other outcomes of interest in oncology, namely, survival, cost, and patient advocacy.

4.1. Clinical and Public Health Implications

Considering that less than five percent of cancer survivors enroll in medical clinical trials [64,65], the use of real-world clinical data, as we used in this study, is critical to understanding the efficacy of PT/OT services in the community. This allows for a pragmatic evaluation of changes in HRQOL when delivered in contexts representing those that a survivor, at least in the USA, is more likely to experience [66]. We were able to evaluate a larger, more representative sample than would typically be enrolled in a clinical trial, moving toward a broader population-level impact of real-world services (i.e., generalizable and sustainable). Similar improvements in health-related quality of life have been observed in other countries and healthcare settings, including the inpatient setting [67,68,69,70]. For example, Licht et al. (2021) used a similar study design to ours to investigate the effects of an inpatient rehabilitation program in Austria [67]. In their study, which included over 4000 inpatients with various diagnosis types, Licht et al. observed significant improvements in global HRQOL scores. However, many patients reported additional needs upon discharge from inpatient rehabilitation [67,69], often leading to subsequent hospitalization [70]. These needs can and should be managed in the outpatient setting with the goals of keeping patients out of hospital and maximizing HRQOL long-term. The results of this study can be used to enhance access to outpatient cancer rehabilitation services by educating oncology clinicians, survivors, policymakers, and payors on the benefits of these services [23].
For oncology providers, improved integration of specialized outpatient PT/OT services into comprehensive cancer care may be the key to addressing the unmet HRQOL needs of survivors. Outpatient cancer rehabilitation is a relatively low-cost service that is generally covered by insurance. In previous studies of individuals with cancer who attend cancer rehabilitation, patient-rated acceptability was high and most agreed they would recommend the service to others because they could recognize the value in attending [50]. For cancer survivors, previous studies have qualitatively described a lack of understanding of cancer rehabilitation as a barrier to participation [32,33]. These data, coupled with other evidence demonstrating the importance of survivors experiencing an improvement in how they feel [50], relate to the importance of evaluating HRQOL as an outcome of rehabilitation. This study can help inform survivors of what they expect from cancer rehabilitation services, providing an incentive to attend. These positive findings may also interest payors, showing that rehabilitation offers a low-cost means to enhance the outcome of high importance: HRQOL. Finally, this study can be used by researchers, rehabilitation clinicians, or administrators to optimize the translation of research evidence to clinical practice by informing outcome selection, research study design, sample sizes for grants, and future program evaluations.

4.2. Limitations and Future Directions

Owing to the nature of real-world data, this study was limited by the variables available within the rehabilitation medical record, which did not include variables such as cancer stage, grade, date of diagnosis, cancer treatments received, cancer treatment status (active or post-treatment), or reasons for referral that may be available in a more comprehensive medical record, these factors may affect the impact of the intervention. In future studies, researchers should include additional cancer diagnosis (e.g., stage, grade, and time since diagnosis), treatment characteristics (i.e., treatment received and timing), and other health behaviors and supports in their analysis to provide additional understanding of the influence of these factors on the benefits of rehabilitation services. The following considerations may also affect the generalizability of these findings to rehabilitation services delivered outside of this large rehabilitation network in the United States or delivered in other countries. The de-identified dataset used for analysis prevented us from being able to identify cases who may have received multidisciplinary (PT and OT) services and to examine potential differences in cases who completed pre/post outcomes as compared to those who did not. In addition, OT utilization in this study was relatively low (7% of all cases). The authors have previously described the unique role and value of OT services for adults living with and beyond cancer [71], including activities of daily living, participation in life situations, mental health, cognitive function, and overall HRQOL. Additional research and advocacy efforts are needed to expand the cancer-specialized rehabilitation workforce beyond PT to meet the needs of survivors and their caretakers and to advocate for the unique role and benefits of each type of service.
In addition, future studies could build on this study and evaluate the cost–benefit to patients (e.g., out-of-pocket costs compared to costs of longer-term disability and loss of work), providers (e.g., in value-based care models looking to optimize outcomes, unplanned hospitalization, long-term care use, and increased patient satisfaction), and the healthcare system, US as well as others, at large (e.g., payors save money by offering PT/OT earlier and more often to beneficiaries). This could add to our understanding of the value that cancer rehabilitation can bring to all key members.

5. Conclusions

In this large retrospective study, we observed statistically and clinically significant improvements in HRQOL domains reported by over 1400 cancer survivors in 12 unique cancer types who received PT/OT. At evaluation, on average, survivors reported their HRQOL below general population norms, suggesting significant needs, including decreased physical function and social participation. At discharge, HRQOL improved to or above the general population norms for several cancer types. This study builds upon previous work describing the need for improved integration of supportive care and the effectiveness of cancer rehabilitation by demonstrating the population-level impacts observed in a national outpatient cancer rehabilitation program. Future studies to determine the best practices to integrate cancer rehabilitation services into existing oncology workflows and define the cost benefits and survival implications of the service are warranted.

Author Contributions

Conceptualization—M.P., K.C.W., T.D.K. and S.M., Data curation and formal analysis—K.C.W., Methodology—M.P. and K.C.W., Project Administration—K.C.W., Supervision—M.P., Writing—Original draft—M.P., K.C.W. and T.D.K., Writing—review and editing—all. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

This study was approved by the Institutional Review Board at the University of Southern Maine (protocol number: 21-07-1714, approval date: 29 July 2021).

Informed Consent Statement

Not applicable.

Data Availability Statement

Data available by request is subject to approval.

Acknowledgments

We would like to thank all the individuals who completed cancer rehabilitation services and their therapists. We would also like to thank Dave Hopwood, MSHHI, and Kim Love, PhD.

Conflicts of Interest

The authors Pergolotti, Wood, Kendig, and Mayo received salaries from Select Medical. The authors have no other relevant financial or non-financial interests to disclose. The content is the sole responsibility of the authors and does not necessarily represent the official views of Select Medical.

References

  1. Cespedes Feliciano, E.M.; Vasan, S.; Luo, J.; Binder, A.M.; Rowan, S.; Chlebowski, T.; Quesenberry, C.; Banack, H.R.; Caan, B.J.; Paskett, E.D.; et al. Long-term Trajectories of Physical Function Decline in Women with and without Cancer. JAMA Oncol. 2023, 9, 395–403. [Google Scholar] [CrossRef]
  2. Weaver, K.E.; Forsythe, L.P.; Reeve, B.B.; Alfano, C.M.; Rodriguez, J.L.; Sabatino, S.A.; Hawkins, N.A.; Rowland, J.H. Mental and physical health-related quality of life among U.S. cancer survivors: Population estimates from the 2010 National Health Interview Survey. Cancer Epidemiol. Biomark. Prev. 2012, 21, 2108–2117. [Google Scholar] [CrossRef]
  3. Sanchez-Jimenez, A.; Cantarero-Villanueva, I.; Delgado-Garcia, G.; Molina-Barea, R.; Fernandez-Lao, C.; Galiano-Castillo, N.; Arroyo-Morales, M. Physical impairments and quality of life of colorectal cancer survivors: A case-control study. Eur. J. Cancer Care 2015, 24, 642–649. [Google Scholar] [CrossRef]
  4. Spoelstra, S.L.; Given, B.A.; Schutte, D.L.; Sikorskii, A.; You, M.; Given, C.W. Do Older Adults with Cancer Fall More Often? A Comparative Analysis of Falls in Those with and without Cancer. Oncol. Nurs. Forum. 2013, 40, E69–E78. [Google Scholar] [CrossRef]
  5. Moghaddam, N.; Coxon, H.; Nabarro, S.; Hardy, B.; Cox, K. Unmet care needs in people living with advanced cancer: A systematic review. Support Care Cancer 2016, 24, 3609–3622. [Google Scholar] [CrossRef]
  6. Reb, A.M.; Cope, D.G. Quality of Life and Supportive Care Needs of Gynecologic Cancer Survivors. West J. Nurs. Res. 2019, 41, 1385–1406. [Google Scholar] [CrossRef]
  7. Pergolotti, M.; Bailliard, A.; McCarthy, L.; Farley, E.; Covington, K.R.; Doll, K.M. Women’s Experiences After Ovarian Cancer Surgery: Distress, Uncertainty, and the Need for Occupational Therapy. Am. J. Occup. Ther. 2020, 74, 7403205140p1–7403205140p9. [Google Scholar] [CrossRef]
  8. Vu, J.V.T.; Matusko, N.; Hendren, S.; Regenbogen, S.E.; Hardiman, K.M. Patient-Reported Unmet Needs in Colorectal Cancer Survivors After Treatment for Curative-Intent. Dis. Colon Rectum 2019, 62, 815. [Google Scholar] [CrossRef]
  9. Paterson, C.; Robertson, A.; Smith, A.; Nabi, G. Identifying the unmet supportive care needs of men living with and beyond prostate cancer: A systematic review. Eur. J. Oncol. Nurs. 2015, 19, 405–418. [Google Scholar] [CrossRef]
  10. Ringash, J.; Bernstein, L.J.; Devins, G.; Dunphy, C.; Giuliani, M.; Martino, R.; McEwen, S. Head and Neck Cancer Survivorship: Learning the Needs, Meeting the Needs. Semin. Radiat. Oncol. 2018, 28, 64–74. [Google Scholar] [CrossRef]
  11. Bayly, J.L.; Lloyd-Williams, M. Identifying functional impairment and rehabilitation needs in patients newly diagnosed with inoperable lung cancer: A structured literature review. Support Care Cancer 2016, 24, 2359–2379. [Google Scholar] [CrossRef]
  12. Sitlinger, A.; Zafar, S.Y. Health-Related Quality of Life: The Impact on Morbidity and Mortality. Surg. Oncol. Clin. N. Am. 2018, 27, 675. [Google Scholar] [CrossRef]
  13. Sitlinger, A.; Shelby, R.A.; Van Denburg, A.N.; White, H.; Edmond, S.N.; Marcom, P.K.; Bosworth, H.B.; Keefe, F.J.; Kimmick, G.G. Higher symptom burden is associated with lower function in women taking adjuvant endocrine therapy for breast cancer. J. Geriatr. Oncol. 2019, 10, 317–321. [Google Scholar] [CrossRef]
  14. Efficace, F.; Bottomley, A.; Coens, C.; Van Steen, K.; Conroy, T.; Schöffski, P.; Schmoll, H.; Van Cutsem, E.; Köhne, C.H. Does a patient’s self-reported health-related quality of life predict survival beyond key biomedical data in advanced colorectal cancer? Eur. J. Cancer 2006, 42, 42–49. [Google Scholar] [CrossRef]
  15. Lund, C.M.; Vistisen, K.K.; Dehlendorff, C.; Ronholt, F.; Johansen, J.S.; Nielsen, D.L. The effect of geriatric intervention in frail older patients receiving chemotherapy for colorectal cancer: A randomised trial (GERICO). Clin. Study Br. J. Cancer 2021, 124, 1949–1958. [Google Scholar] [CrossRef]
  16. Clough-Gorr, K.M.; Stuck, A.E.; Thwin, S.S.; Silliman, R.A. Older Breast Cancer Survivors: Geriatric Assessment Domains Are Associated with Poor Tolerance of Treatment Adverse Effects and Predict Mortality Over 7 Years of Follow-Up. J. Clin. Oncol. 2010, 28, 380–386. [Google Scholar] [CrossRef]
  17. Sannes, T.S.; Simoneau, T.L.; Mikulich-Gilbertson, S.K.; Natvig, C.L.; Brewer, B.W.; Kilbourn, K.; Laudenslager, M.L. Distress and quality of life in patient and caregiver dyads facing stem cell transplant: Identifying overlap and unique contributions. Support Care Cancer 2019, 27, 2329–2337. [Google Scholar] [CrossRef]
  18. Wu, H.-S.; Harden, J.K. Symptom Burden and Quality of Life in Survivorship. Cancer Nurs. 2015, 38, E29–E54. [Google Scholar] [CrossRef]
  19. Williams, G.R.; Dunham, L.; Chang, Y.K.; Deal, A.M.; Pergolotti, M.; Lund, J.L.; Guerard, E.; Kenzik, K.; Muss, H.B.; Sanoff, H.K. Geriatric Assessment Predicts Hospitalization Frequency and Long-Term Care Use in Older Adult Cancer Survivors. J. Oncol. Pract. 2019, 15, E399–E409. [Google Scholar] [CrossRef]
  20. Bluethmann, S.M.; Mariotto, A.B.; Rowland, J.H. Anticipating the “Silver Tsunami”: Prevalence Trajectories and Comorbidity Burden among Older Cancer Survivors in the United States. Cancer Epidemiol. Biomark. Prev. 2016, 25, 1029–1036. [Google Scholar] [CrossRef]
  21. Alfano, C.M.; Leach, C.R.; Smith, T.G.; Miller, K.D.; Alcaraz, K.I.; Cannady, R.S.; Wender, R.C.; Brawley, O.W. Equitably improving outcomes for cancer survivors and supporting caregivers: A blueprint for care delivery, research, education, and policy. CA Cancer J. Clin. 2019, 69, 35–49. [Google Scholar] [CrossRef]
  22. Levit, L.A.; Balogh, E.P.; Nass, S.J.; Ganz, P.A. (Eds.) Delivering High-Quality Cancer Care: Charting a New Course for a System in Crisis; The National Academies Press: Washington, DC, USA, 2013. [Google Scholar] [CrossRef]
  23. Pergolotti, M.; Alfano, C.M.; Cernich, A.N.; Yabroff, K.R.; Manning, P.R.; de Moor, J.S.; Hahn, E.E.; Cheville, A.L.; Mohile, S.G. A health services research agenda to fully integrate cancer rehabilitation into oncology care. Cancer 2019, 125, 3908–3916. [Google Scholar] [CrossRef]
  24. Alfano, C.M.; Pergolotti, M. Next-Generation Cancer Rehabilitation: A Giant Step Forward for Patient Care. Rehabil. Nurs. 2018, 43, 186–194. [Google Scholar] [CrossRef]
  25. Brick, R.; Padgett, L.; Jones, J.; Wood, K.C.; Pergolotti, M.; Marshall, T.F.; Campbell, G.; Eilers, R.; Keshavarzi, S.; Flores, A.M.; et al. The influence of telehealth-based cancer rehabilitation interventions on disability: A systematic review. J. Cancer Surviv. 2022, 17, 1725–1750. [Google Scholar] [CrossRef]
  26. Sleight, A.; Gerber, L.H.; Marshall, T.F.; Livinski, A.; Alfano, C.M.; Harrington, S.; Flores, A.M.; Virani, A.; Hu, X.; Mitchell, S.A.; et al. Systematic Review of Functional Outcomes in Cancer Rehabilitation. Arch. Phys. Med. Rehabil. 2022, 103, 1807–1826. [Google Scholar] [CrossRef]
  27. Hunter, E.G.; Gibson, R.W.; Arbesman, M.; D’Amico, M. Systematic Review of Occupational Therapy and Adult Cancer Rehabilitation: Part 1. Impact of Physical Activity and Symptom Management Interventions. Am. J. Occup. Ther. 2017, 71, 7102100030p1–7102100030p11. [Google Scholar] [CrossRef]
  28. Hunter, E.G.; Gibson, R.W.; Arbesman, M.; D’Amico, M. Systematic Review of Occupational Therapy and Adult Cancer Rehabilitation: Part 2. Impact of Multidisciplinary Rehabilitation and Psychosocial, Sexuality, and Return-to-Work Interventions. Am. J. Occup. Ther. 2017, 71, 7102100040p1–7102100040p8. [Google Scholar] [CrossRef]
  29. Longacre, C.F.; Nyman, J.A.; Visscher, S.L.; Borah, B.J.; Cheville, A.L. Cost-effectiveness of the Collaborative Care to Preserve Performance in Cancer (COPE) trial tele-rehabilitation interventions for patients with advanced cancers. Cancer Med. 2020, 9, 2723–2731. [Google Scholar] [CrossRef]
  30. Mewes, J.C.; Steuten, L.M.G.; IJzerman, M.J.; van Harten, W.H. Effectiveness of Multidimensional Cancer Survivor Rehabilitation and Cost-Effectiveness of Cancer Rehabilitation in General: A Systematic Review. Oncologist 2012, 17, 1581–1593. [Google Scholar] [CrossRef]
  31. Bruce, J.; Mazuquin, B.; Canaway, A.; Hossain, A.; Williamson, E.; Mistry, P.; Lall, R.; Petrou, S.; Lamb, S.E.; Rees, S.; et al. Exercise versus usual care after non-reconstructive breast cancer surgery (UK PROSPER): Multicentre randomised controlled trial and economic evaluation. BMJ 2021, 375, e066542. [Google Scholar] [CrossRef]
  32. Pergolotti, M.; Deal, A.M.; Williams, G.R.; Bryant, A.L.; McCarthy, L.; Nyrop, K.A.; Covington, K.R.; Reeve, B.B.; Basch, E.; Muss, H.B. Older Adults with Cancer: A Randomized Controlled Trial of Occupational and Physical Therapy. J. Am. Geriatr. Soc. 2019, 67, 953–960. [Google Scholar] [CrossRef]
  33. Brick, R.; Lyons, K.D.; Bender, C.; Eilers, R.; Ferguson, R.; Pergolotti, M.; Toto, P.; Skidmore, E.; Leland, N.E. Factors influencing utilization of cancer rehabilitation services among older breast cancer survivors in the USA: A qualitative study. Support Care Cancer 2022, 30, 2397–2405. [Google Scholar] [CrossRef]
  34. Pergolotti, M.; Wood, K.C.; Kendig, T. The broader impact of specialized outpatient cancer rehabilitation on health and quality of life among breast cancer survivors. J. Clin. Oncol. 2023, 41 (Suppl. 16), e18881. [Google Scholar] [CrossRef]
  35. Motheral, B.; Brooks, J.; Clark, M.A.; Crown, W.H.; Davey, P.; Hutchins, D.; Martin, B.C.; Stang, P. A Checklist for Retrospective Database Studies—Report of the ISPOR Task Force on Retrospective Databases. Value Health 2003, 6, 90–97. [Google Scholar] [CrossRef]
  36. Ader, D.N. Developing the Patient-Reported Outcomes Measurement Information System (PROMIS). Med. Care 2007, 45. [Google Scholar] [CrossRef]
  37. Cella, D.; Riley, W.; Stone, A.; Rothrock, N.; Reeve, B.; Yount, S.; Amtmann, D.; Bode, R.; Buysse, D.; Choi, S.; et al. The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005–2008. J. Clin. Epidemiol. 2010, 63, 1179–1194. [Google Scholar] [CrossRef]
  38. Reeve, B.B.; Hays, R.D.; Bjorner, J.B.; Cook, K.; Crane, P.K.; Teresi, J.A.; Thissen, D.; Revicki, D.A.; Weiss, D.J.; Hambleton, H.L.; et al. Psychometric Evaluation and Calibration of Health-Related Quality of Life Item Banks: Plans for the Patient-Reported Outcomes Measurement Information System (PROMIS). Med. Care 2007, 45, S22–S31. [Google Scholar] [CrossRef]
  39. Schalet, B.D.; Hays, R.D.; Jensen, S.E.; Beaumont, J.L.; Fries, J.F.; Cella, D. Validity of PROMIS physical function measured in diverse clinical samples. J. Clin. Epidemiol. 2016, 73, 112–118. [Google Scholar] [CrossRef]
  40. Hays, R.D.; Spritzer, K.L.; Thompson, W.W.; Cella, D.U.S. General Population Estimate for “Excellent” to “Poor” Self-Rated Health Item. J. Gen. Intern. Med. 2015, 30, 1511. [Google Scholar] [CrossRef]
  41. Jensen, R.E.; Moinpour, C.M.; Potosky, A.L.; Lobo, T.; Hahn, E.A.; Hays, R.D.; Cella, D.; Smith, A.W.; Wu, X.C.; Keegan, T.H.M.; et al. Responsiveness of 8 PROMIS® Measures in a Large, Community-Based Cancer Study Cohort. Cancer 2017, 123, 327. [Google Scholar] [CrossRef]
  42. Terwee, C.B.; Peipert, J.D.; Chapman, R.; Lai, J.S.; Terluin, B.; Cella, D.; Griffith, P.; Mokkink, L.B. Minimal important change (MIC): A conceptual clarification and systematic review of MIC estimates of PROMIS measures. Qual. Life Res. 2021, 30, 2729–2754. [Google Scholar] [CrossRef]
  43. Shaw, B.E.; Syrjala, K.L.; Onstad, L.E.; Chow, E.J.; Flowers, M.E.; Jim, H.; Baker, K.S.; Buckley, S.; Fairclough, D.L.; Horowitz, M.M.; et al. PROMIS measures can be used to assess symptoms and function in long-term hematopoietic cell transplantation survivors. Cancer 2018, 124, 841–849. [Google Scholar] [CrossRef]
  44. Seneviratne, M.G.; Bozkurt, S.; Patel, M.I.; Seto, T.; Brooks, J.D.; Blayney, D.W.; Kurian, A.W.; Hernandez-Boussard, T. Distribution of global health measures from routinely collected PROMIS surveys in patients with breast cancer or prostate cancer. Cancer 2019, 125, 943–951. [Google Scholar] [CrossRef]
  45. Gressel, G.M.; Dioun, S.M.; Richley, M.; Lounsbury, D.W.; Rapkin, B.D.; Isani, S.; Nevadunsky, N.S.; Kuo, D.Y.S.; Novetsky, A.P. Utilizing the Patient Reported Outcomes Measurement Information System (PROMIS®) to increase referral to ancillary support services for severely symptomatic patients with gynecologic cancer. Gynecol. Oncol. 2019, 152, 509–513. [Google Scholar] [CrossRef]
  46. Leung, Y.W.; Brown, C.; Cosio, A.P.; Dobriyal, A.; Malik, N.; Pat, V.; Irwin, M.; Tomasini, P.; Liu, G.; Howell, D. Feasibility and diagnostic accuracy of the Patient-Reported Outcomes Measurement Information System (PROMIS) item banks for routine surveillance of sleep and fatigue problems in ambulatory cancer care. Cancer 2016, 122, 2906–2917. [Google Scholar] [CrossRef]
  47. Wagner, L.I.; Schink, J.; Bass, M.; Patel, S.; Diaz, M.V.; Rothrock, N.; Pearman, T.; Gershon, R.; Penedo, F.J.; Rosen, S.; et al. Bringing PROMIS to practice: Brief and precise symptom screening in ambulatory cancer care. Cance 2015, 121, 927–934. [Google Scholar] [CrossRef]
  48. Hays, R.D.; Bjorner, J.B.; Revicki, D.A.; Spritzer, K.L.; Cella, D. Development of physical and mental health summary scores from the patient-reported outcomes measurement information system (PROMIS) global items. Qual. Life Res. 2009, 18, 873–880. [Google Scholar] [CrossRef]
  49. R Core Team. R: A Language and Environment for Statistical Computing. 2021. Available online: https://www.r-project.org/ (accessed on 4/10/2023).
  50. Wood, K.C.; Bertram, J.J.; Kendig, T.D.; Pergolotti, M. Understanding Patient Experience with Outpatient Cancer Rehabilitation Care. Healthcare 2023, 11, 348. [Google Scholar] [CrossRef]
  51. Wood, K.C.; Hidde, M.; Kendig, T.; Pergolotti, M. Community-based outpatient rehabilitation for the treatment of breast cancer-related upper extremity disability: An evaluation of practice-based evidence. Breast Cancer 2022, 29, 1099–1105. [Google Scholar] [CrossRef]
  52. Wood, K.C.; Bertram, J.; Kendig, T.; Hidde, M.; Leiser, A.; Buckley de Meritens, A.; Pergolotti, M. Community-based outpatient cancer rehabilitation services for women with gynecologic cancer: Acceptability and impact on patient-reported outcomes. Support Care Cancer 2022, 30, 8089–8099. [Google Scholar] [CrossRef]
  53. Pergolotti, M.; Covington, K.R.; Lightner, A.N.; Bertram, J.; Thess, M.; Sharp, J.; Spraker, M.; Williams, G.R.; Manning, P. Association of Outpatient Cancer Rehabilitation with Patient-Reported Outcomes and Performance-Based Measures of Function. Rehabil. Oncol. 2021, 39, 137–142. [Google Scholar] [CrossRef]
  54. Pergolotti, M.; Deal, A.M.; Lavery, J.; Reeve, B.B.; Muss, H.B. The prevalence of potentially modifiable functional deficits and the subsequent use of occupational and physical therapy by older adults with cancer. J. Geriatr. Oncol. 2015, 6, 194–201. [Google Scholar] [CrossRef] [PubMed]
  55. Brick, R.; Natori, A.; Moreno, P.I.; Molinares, D.; Koru-Sengul, T.; Penedo, F.J. Predictors of cancer rehabilitation medicine referral and utilization based on the Moving Through Cancer physical activity screening assessment. Support Care Cancer 2023, 31, 216. [Google Scholar] [CrossRef]
  56. Al Obaidi, M.; Giri, S.; Mir, N.; Kenzik, K.; McDonald, A.M.; Smith, C.Y.; Gbolahan, O.B.; Paluri, R.K.; Bhatia, S.; Williams, G.R. Use of self-rated health to identify frailty and predict mortality in older adults with cancer. Results from the care study. J. Clin. Oncol. 2020, 38 (Suppl. S15), 12046. [Google Scholar] [CrossRef]
  57. Leach, C.R.; Gapstur, S.M.; Cella, D.; Deubler, E.; Teras, L.R. Age-related health deficits and five-year mortality among older, long-term cancer survivors. J. Geriatr. Oncol. 2022, 13, 1023–1030. [Google Scholar] [CrossRef] [PubMed]
  58. Neal, J.W.; Roy, M.; Bugos, K.; Sharp, C.; Galatin, P.S.; Falconer, P.; Rosenthal, E.L.; Blayney, D.W.; Modaressi, S.; Robinson, A.; et al. Distress Screening Through Patient-Reported Outcomes Measurement Information System (PROMIS) at an Academic Cancer Center and Network Site: Implementation of a Hybrid Model. JCO Oncol. Pract. 2021, 17, e1688–e1697. [Google Scholar] [CrossRef] [PubMed]
  59. Carlson, L.E.; Zelinski, E.L.; Toivonen, K.I.; Sundstrom, L.; Jobin, C.T.; Damaskos, P.; Zebrack, B. Prevalence of psychosocial distress in cancer patients across 55 North American cancer centers. J. Psychosoc. Oncol. 2019, 37, 5–21. [Google Scholar] [CrossRef] [PubMed]
  60. Firkins, J.; Hansen, L.; Driessnack, M.; Dieckmann, N. Quality of life in “chronic” cancer survivors: A meta-analysis. J. Cancer Surviv. 2020, 14, 504–517. [Google Scholar] [CrossRef] [PubMed]
  61. Harrison, J.M.; Stella, P.J.; LaVasseur, B.; Adams, P.T.; Swafford, L.; Lewis, J.; Mendelsohn-Victor, K.; Friese, C.R. Toxicity-Related Factors Associated with Use of Services Among Community Oncology Patients. J. Oncol. Pract. 2016, 12, e818–e827. [Google Scholar] [CrossRef]
  62. Jacobs, J.M.; Ream, M.E.; Pensak, N.; Nisotel, L.E.; Fishbein, J.N.; MacDonald, J.J.; Buzaglo, J.; Lennes, I.T.; Safren, S.A.; Pirl, W.F.; et al. Patient Experiences with Oral Chemotherapy: Adherence, Symptoms, and Quality of Life. J. Natl. Compr. Cancer Netw. 2019, 17, 221–228. [Google Scholar] [CrossRef]
  63. Kirkhus, L.; Harneshaug, M.; Saltyte Benth, J.; Gronberg, B.H.; Rostoft, S.; Bergh, S.; Hjermstad, M.J.; Selbaek, G.; Wyller, T.B.; Kirkevold, O.; et al. Modifiable factors affecting older patients’ quality of life and physical function during cancer treatment. J. Geriatr. Oncol. 2019, 10, 904–912. [Google Scholar] [CrossRef] [PubMed]
  64. Duma, N.; Aguilera, J.V.; Paludo, J.; Haddox, C.L.; Velez, M.G.; Wang, Y.; Leventakos, K.; Hubbard, J.M.; Mansfield, A.S.; Go, R.S.; et al. Representation of Minorities and Women in Oncology Clinical Trials: Review of the Past 14 Years. J. Oncol. Pract. 2018, 14, e1–e10. [Google Scholar] [CrossRef] [PubMed]
  65. Murthy, V.H.; Krumholz, H.M.; Gross, C.P. Participation in Cancer Clinical Trials: Race-, Sex-, and Age-Based Disparities. JAMA 2004, 291, 2720–2726. [Google Scholar] [CrossRef] [PubMed]
  66. Penberthy, L.T.; Rivera, D.R.; Lund, J.L.; Bruno, M.A.; Meyer, A.-M. An overview of real-world data sources for oncology and considerations for research. CA Cancer J. Clin. 2022, 72, 287–300. [Google Scholar] [CrossRef]
  67. Licht, T.; Nickels, A.; Rumpold, G.; Holzner, B.; Riedl, D. Evaluation by electronic patient-reported outcomes of cancer survivors’ needs and the efficacy of inpatient cancer rehabilitation in different tumor entities. Support Care Cancer 2021, 29, 5853–5864. [Google Scholar] [CrossRef] [PubMed]
  68. Riedl, D.; Giesinger, J.M.; Wintner, L.M.; Loth, F.L.; Rumpold, G.; Greil, R.; Nickels, A.; Licht, T.; Holzner, B. Improvement of quality of life and psychological distress after inpatient cancer rehabilitation: Results of a longitudinal observational study. Wien. Klin. Wochenschr. 2017, 129, 692–701. [Google Scholar] [CrossRef] [PubMed]
  69. Faller, H.; Hass, H.G.; Engehausen, D.; Reuss-Borst, M.; Wöckel, A. Supportive care needs and quality of life in patients with breast and gynecological cancer attending inpatient rehabilitation. A prospective study. Acta Oncol. 2019, 58, 417–424. [Google Scholar] [CrossRef] [PubMed]
  70. Tennison, J.M.; Rianon, N.J.; Manzano, J.G.; Munsell, M.F.; George, M.C.; Bruera, E. Thirty-day hospital readmission rate, reasons, and risk factors after acute inpatient cancer rehabilitation. Cancer Med. 2021, 10, 6199. [Google Scholar] [CrossRef]
  71. Pergolotti, M.; Williams, G.R.; Campbell, C.; Munoz, L.A.; Muss, H.B. Occupational Therapy for Adults with Cancer: Why It Matters. Oncologist 2016, 21, 314–319. [Google Scholar] [CrossRef]
Table 1. Characteristics of cancer survivors participating in outpatient cancer PT/OT, N = 1415.
Table 1. Characteristics of cancer survivors participating in outpatient cancer PT/OT, N = 1415.
CharacteristicMean ± SD, N, %
Age (Mean ± SD, range)65.45 ± 12.84, 19.0–91.0
Sex (n, %)
Female650, 45.9%
Male765, 54.1%
Race/ethnicity (n, %) a
White538, 80.7%
Black/African American63, 9.4%
Hispanic38, 5.7%
Asian or Pacific Islander27, 4.1%
United States region
South585, 39.8%
Northeast385, 26.2%
Southeast241, 16.4%
Midwest177, 12.0%
West82, 5.6%
Insurer type
Federally funded879, 62.1%
Private or self-pay536, 37.89%
Cancer type
Head and neck257, 18.2%
Lung169, 11.9%
Gynecologic158, 11.2%
Prostate146, 10.3%
Colorectal118, 8.3%
Multiple Myeloma111, 7.6%
Lymphoma98, 6.9%
Gastrointestinal83, 5.9%
Genitourinary75, 5.3%
Pancreatic70, 4.9%
Leukemia66, 4.7%
Brain, spinal cord, nervous system64, 4.5%
Rehabilitation service type (N, %)
PT1314, 92.9%
OT101, 7.1%
Visits completed (Median, IQR)12.00, 8.00–19.00
Length of care, weeks (Median, IQR)28.00, 9.14–80.00
a Race, N = 666. Data unavailable for 52.9%.
Table 2. Pre- and Post-Rehabilitation PROMIS® Global Physical Health (GPH) T-scores, by Cancer Diagnosis Type.
Table 2. Pre- and Post-Rehabilitation PROMIS® Global Physical Health (GPH) T-scores, by Cancer Diagnosis Type.
NInitial Evaluation
EM Mean, SE		Discharge
EM Mean, SE		EM Mean Change, SEp-ValueAchieved MIC
Head and neck25744.45, 0.52648.41, 0.5263.96, 0.471 †<0.001 **61.9%
Lung16939.04, 0.59843.02, 0.5983.97, 0.596 †<0.001 **63.9%
Gynecologic15839.54, 0.52643.90, 0.5264.36, 0.489 †<0.001 **67.7%
Prostate14641.64, 0.66744.88, 0.6673.24, 0.503 †<0.001 **60.3%
Colorectal11842.07, 0.72845.00, 0.7282.93, 0.587 †<0.001 **61.9%
Multiple Myeloma11139.18, 0.73942.58, 0.7393.40, 0.601 †0.001 **64.0%
Lymphoma9839.77, 0.83143.67, 0.8313.89, 0.645 †<0.001 **65.3%
Gastrointestinal8339.14, 0.81042.51, 0.8103.37, 0.850 †<0.001 **65.1%
Genitourinary7542.08, 1.0445.21, 1.043.13, 0.872 †0.001 **49.3%
Pancreatic7038.81, 0.77841.88, 0.7783.07, 0.777 †<0.001 **61.4%
Leukemia6640.25, 0.95845.39, 0.9585.15, 0.810 †<0.001 **71.2%
Brain, spinal cord, nervous system6440.74, 0.96744.90, 0.9674.16, 1.02 †<0.001 **68.8%
Pre- to post-rehabilitation within-group change, p < 0.05. ** Pre- to post-rehabilitation within-group change, p < 0.01. † Estimated marginal (EM) mean change exceeded the minimal important change (MIC; 2 points) [42]. EM means adjusted for the following covariates: age, sex, rehabilitation service type (PT or OT), visits, and length of care.
Table 3. Pre- and Post-Rehabilitation PROMIS® Global Mental Health (GMH) T-scores, by Cancer Diagnosis Type.
Table 3. Pre- and Post-Rehabilitation PROMIS® Global Mental Health (GMH) T-scores, by Cancer Diagnosis Type.
NInitial Evaluation
EM Mean, SE		Discharge
EM Mean, SE		EM Mean Change, SEp-ValueAchieved MIC
Head and neck25748.93, 0.56351.02, 0.5631.92, 1.12<0.001 **52.1%
Lung16945.67, 0.65048.59, 0.6501.83, 0.580<0.001 **55%
Gynecologic15846.42, 0.64748.82, 0.6472.20, 0.850 †<0.001 **51.9%
Prostate14648.54, 0.71650.35, 0.7161.83, 0.8830.002 **56.8%
Colorectal11847.45, 0.80149.28, 0.8012.40, 0.550 †0.002 *46.6%
Multiple Myeloma11145.80, 0.77047.88, 0.7702.09, 0.497 †0.001 **56.8%
Lymphoma9846.94, 0.95448.88, 0.9542.72, 0.722 †0.005 **53.1%
Gastrointestinal8345.82, 0.93847.66, 0.9382.93, 0.584 †<0.001 **50.6%
Genitourinary7548.75, 0.99650.94, 0.9961.94, 0.6830.012 *57.3%
Pancreatic7044.76, 1.0046.91, 1.002.07, 0.643 †0.020 *48.6%
Leukemia6647.71, 1.0450.43, 1.042.15, 0.901 †<0.001 **63.6%
Brain, spinal cord, nervous system6446.25, 1.0948.17, 1.093.24, 0.503 †0.09151.6%
Pre- to post-rehabilitation within-group change, p < 0.05. ** Pre- to post-rehabilitation within-group change, p < 0.01. † Estimated marginal (EM) mean change exceeded the minimal important change (MIC; 2 points) [42]. EM means adjusted for the following covariates: age, sex, rehabilitation service type (PT or OT), visits, and length of care.
Table 4. Pre- and Post-Rehabilitation PROMIS® Physical Function (PF) T-scores, by Cancer Diagnosis Type.
Table 4. Pre- and Post-Rehabilitation PROMIS® Physical Function (PF) T-scores, by Cancer Diagnosis Type.
NInitial Evaluation
EM Mean, SE		Discharge
EM Mean, SE		EM Mean Change, SEp-ValueAchieved MIC
Head and neck25744.22, 0.57946.88, 0.5792.66, 0.465 †<0.001 **45.0%
Lung16935.20, 0.62539.13, 0.6253.93, 0.601 †<0.001 **53.9%
Gynecologic15837.84, 0.65641.44, 0.6564.36, 0.489 †<0.001 **55.9%
Prostate14639.52, 0.71141.89, 0.7112.37, 0.521 †<0.001 **43.4%
Colorectal11839.53, 0.80842.37, 0.8082.84, 0.550 †<0.001 **51.4%
Multiple Myeloma11137.96, 0.84140.75, 0.8412.78, 0.674 †<0.001 **49.5%
Lymphoma9838.04, 0.77641.11, 0.7763.07, 0.755 †<0.001 **50.0%
Gastrointestinal8336.66, 0.83039.45, 0.8302.79, 0.733 †<0.001 **47.9%
Genitourinary7539.23, 1.0742.19, 1.072.97, 0.883 †0.001 **46.5%
Pancreatic7036.74, 0.89340.00, 0.8933.26, 0.827 †<0.001 **51.5%
Leukemia6636.97, 1.0341.59, 1.034.61, 0.855 †<0.001 **67.2%
Brain, spinal cord, nervous system6435.53, 0.96738.92, 0.9673.39, 0.960 †0.001 **56.6%
Pre- to post-rehabilitation within-group change, p < 0.05. ** Pre- to post-rehabilitation within-group change, p < 0.01. † Estimated marginal (EM) mean change exceeded the minimal important change (MIC; 2 points) [42]. EM means adjusted for the following covariates: age, sex, rehabilitation service type (PT or OT), visits, and length of care.
Table 5. Pre- and Post-Rehabilitation PROMIS® Ability to Participate in Social Roles and Activities (SRA) T-scores, by Cancer Diagnosis Type.
Table 5. Pre- and Post-Rehabilitation PROMIS® Ability to Participate in Social Roles and Activities (SRA) T-scores, by Cancer Diagnosis Type.
NInitial Evaluation
EM Mean, SE		Discharge
EM Mean, SE		EM Mean Change, SEp-ValueAchieved MIC
Head and neck25749.98, 0.62852.50, 0.6282.52, 0.625 †<0.001 **45.1%
Lung16943.24, 0.68047.21, 0.6803.97, 0.670 †<0.001 **55.9%
Gynecologic15844.84, 0.71847.87, 0.7183.03, 0.711 †<0.001 **53.0%
Prostate14647.00, 0.79149.16, 0.7912.16, 0.686 †00.002 **40.8%
Colorectal11845.72, 0.82248.88, 0.8223.16, 0.695 †<0.001 **49.1%
Multiple Myeloma11143.77, 0.81747.23, 0.8173.46, 0.766 †<0.001 **48.4%
Lymphoma9845.05, 0.94548.26, 0.9453.21, 0.886 †<0.001 **52.2%
Gastrointestinal8343.40, 1.0347.30, 1.033.90, 0.850 †0.001 **57.1%
Genitourinary7545.19, 1.0848.78, 1.083.59, 0.992 †0.001 **47.8%
Pancreatic7042.08, 0.84646.38, 0.8464.31, 0.802 †<0.001 **57.6%
Leukemia6645.12, 1.1850.65, 1.185.53, 1.02 †<0.001 **64.5%
Brain, spinal cord, nervous system6442.84, 1.2346.73, 1.234.16, 1.02 †0.003 **48.1%
Pre- to post-rehabilitation within-group change, p < 0.05. ** Pre- to post-rehabilitation within-group change, p < 0.01. † Estimated marginal (EM) mean change exceeded the minimal important change (MIC; 2 points) [42]. EM means adjusted for the following covariates: age, sex, rehabilitation service type (PT or OT), visits, and length of care.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Pergolotti, M.; Wood, K.C.; Kendig, T.D.; Mayo, S. Impact of Real-World Outpatient Cancer Rehabilitation Services on Health-Related Quality of Life of Cancer Survivors across 12 Diagnosis Types in the United States. Cancers 2024, 16, 1927. https://doi.org/10.3390/cancers16101927

AMA Style

Pergolotti M, Wood KC, Kendig TD, Mayo S. Impact of Real-World Outpatient Cancer Rehabilitation Services on Health-Related Quality of Life of Cancer Survivors across 12 Diagnosis Types in the United States. Cancers. 2024; 16(10):1927. https://doi.org/10.3390/cancers16101927

Chicago/Turabian Style

Pergolotti, Mackenzi, Kelley C. Wood, Tiffany D. Kendig, and Stacye Mayo. 2024. "Impact of Real-World Outpatient Cancer Rehabilitation Services on Health-Related Quality of Life of Cancer Survivors across 12 Diagnosis Types in the United States" Cancers 16, no. 10: 1927. https://doi.org/10.3390/cancers16101927

APA Style

Pergolotti, M., Wood, K. C., Kendig, T. D., & Mayo, S. (2024). Impact of Real-World Outpatient Cancer Rehabilitation Services on Health-Related Quality of Life of Cancer Survivors across 12 Diagnosis Types in the United States. Cancers, 16(10), 1927. https://doi.org/10.3390/cancers16101927

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop